Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3

被引：0
|
作者：
van de Kerkhof, P. [1 ]
Guenther, L. [2 ]
Gottlieb, A. [3 ]
Sebastian, M. [4 ]
Wu, J. [5 ]
Foley, P. [6 ]
Morita, A. [7 ]
Goldblum, O. [8 ]
Zhang, L. [9 ]
Erickson, J. [9 ]
Ball, S. [9 ]
Rich, P. [10 ]
机构：
[1] Radboud Univ Nijmegan, Med Ctr, Nijmegen, Netherlands
[2] Guenther Dermatol Res Ctr, London, ON, Canada
[3] Tufts Med Ctr, Boston, MA USA
[4] Hautarztpraxis Mahlow, Blankenfelde Mahlow, Germany
[5] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[6] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia
[7] Dept Geriatr & Environm Dermatol, Nagoya, Aichi, Japan
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Oregon Hlth & Sci Univ, Ctr Hlth & Healing, Portland, OR 97201 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
fingernail psoriasis; ixekizumab;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P138
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [1] Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A. B.
    Sebastian, M.
    Wu, J. J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 477 - 482
  • [2] Improvement in nail psoriasis in the open-label extension period of a phase 2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G. G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    Holzkaemper, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 135 - 136
  • [3] Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
    McKevitt, N.
    Rich, P.
    Langley, R. G.
    Menter, A.
    Krueger, G.
    Zhu, B.
    Wei, H.
    Cameron, G. S.
    Heffernan, M. P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 50 - 50
  • [4] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iversen, Lars
    Ball, Susan
    Zhang, Lu
    Agada, Noah O.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
  • [5] Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
    Saeki, H.
    Nakagawa, H.
    Ishii, T.
    Morisaki, Y.
    Aoki, T.
    Berclaz, P. -Y.
    Heffernan, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) : 1148 - 1155
  • [6] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [7] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
    Egeberg, Alexander
    Wu, Jashin J.
    Korman, Neil
    Solomon, James A.
    Goldblum, Orin
    Zhao, Fangyi
    Mallbris, Lotus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
  • [8] Impact of ixekizumab treatment on sexual function in moderate-to-severe psoriasis patients: 12 week results from two phase 3 trials UNCOVER-2 and UNCOVER-3
    Guenther, Lyn
    Sofen, Howard
    Cathers, Jennifer
    Poulin, Yves P.
    Lebwohl, Mark
    Bleakman, Alison Potts
    Zhu, Baojin
    Nikai, Enkeleida
    van de Kerkhof, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB254 - AB254
  • [9] Nail psoriasis as a predictor of skin response to ixekizumab in patients with moderate-to-severe psoriasis
    Rich, P.
    Goldblum, O.
    Amato, D.
    Disch, D.
    Muram, D.
    Merola, J. F.
    Elewski, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S67 - S67
  • [10] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    LANCET, 2015, 386 (9993): : 541 - 551
12345